Alpha 2.0
Login Register
» Authors » Johan W Mouton

Johan W Mouton

Explore the profile of Johan W Mouton including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 232
Citations 6782
Followers 0
Related Specialties
Infectious Diseases
Pharmacology
Microbiology
Top 10 Co-Authors
Paul E Verweij
Joseph Meletiadis
Seyedmojtaba Seyedmousavi
Willem J G Melchers
Anouk E Muller
Ursula Theuretzbacher
Roger J M Bruggemann
Jakko van Ingen
Rixt A Wijma
Mical Paul
Published In
Antimicrob Agents Chemother
J Antimicrob Chemother
Int J Antimicrob Agents
J Clin Microbiol
Clin Infect Dis
Affiliations
Soon will be listed here.
Recent Articles
1.
Binding of temocillin to plasma proteins in vitro and in vivo: the importance of plasma protein levels in different populations and of co-medications
Ngougni Pokem P, Matzneller P, Vervaeke S, Wittebole X, Goeman L, Coessens M, et al.
J Antimicrob Chemother . 2022 Aug; 77(10):2742-2753. PMID: 36018077
Background: Temocillin plasma protein binding (PPB) in healthy individuals is reported to be ∼85% but had not been studied in patients. Objectives: To obtain normative data on temocillin PPB in...
2.
Large-scale WGS of carbapenem-resistant Acinetobacter baumannii isolates reveals patterns of dissemination of ST clades associated with antibiotic resistance
Frenk S, Temkin E, Lurie-Weinberger M, Keren-Paz A, Rov R, Rakovitsky N, et al.
J Antimicrob Chemother . 2022 Jan; 77(4):934-943. PMID: 35084023
Objectives: To describe the population genetics and antibiotic resistance gene distribution of carbapenem-resistant Acinetobacter baumannii (CRAB) isolates causing infections in three Mediterranean countries. Methods: Isolates were collected during the 2013-17...
3.
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
Paul M, Carrara E, Retamar P, Tangden T, Bitterman R, Bonomo R, et al.
Clin Microbiol Infect . 2021 Dec; 28(4):521-547. PMID: 34923128
Scope: These ESCMID guidelines address the targeted antibiotic treatment of third-generation cephalosporin-resistant Enterobacterales (3GCephRE) and carbapenem-resistant Gram-negative bacteria, focusing on the effectiveness of individual antibiotics and on combination versus monotherapy....
4.
Pharmacokinetic/pharmacodynamic analysis of oral fosfomycin against Enterobacterales, Pseudomonas aeruginosa and Enterococcus spp. in an in vitro bladder infection model: impact on clinical breakpoints
Abbott I, Mouton J, Peleg A, Meletiadis J
J Antimicrob Chemother . 2021 Sep; 76(12):3201-3211. PMID: 34473271
Objectives: Fosfomycin is an established treatment for uncomplicated urinary tract infections (UTIs), yet evidence supporting susceptibility breakpoints is limited. We examine the UTI susceptibility criteria. Methods: Fosfomycin susceptibility, heteroresistance and...
5.
The Effect of Antibiotic Restriction Programs on Prevalence of Antimicrobial Resistance: A Systematic Review and Meta-Analysis
Schuts E, Boyd A, Muller A, Mouton J, Prins J
Open Forum Infect Dis . 2021 Apr; 8(4):ofab070. PMID: 33880388
Background: In hospital settings, restriction of selected classes of antibiotics is usually believed to contribute to containment of resistance development. We performed a systematic review and meta-analysis to assess the...
6.
Excluded versus included patients in a randomized controlled trial of infections caused by carbapenem-resistant Gram-negative bacteria: relevance to external validity
Daitch V, Paul M, Daikos G, Durante-Mangoni E, Yahav D, Carmeli Y, et al.
BMC Infect Dis . 2021 Apr; 21(1):309. PMID: 33789574
Background: Population external validity is the extent to which an experimental study results can be generalized from a specific sample to a defined population. In order to apply the results...
7.
Evaluation of the post-antibiotic effect for the combination of a β-lactam antibiotic and a β-lactamase inhibitor: ceftazidime-avibactam in neutropenic mouse thigh and lung infections
Berkhout J, Melchers M, van Mil A, Lagarde C, Nichols W, Mouton J
J Chemother . 2021 Mar; 33(6):400-408. PMID: 33682636
The post-antibiotic effect (PAE) of ceftazidime-avibactam was evaluated using models of thigh- and lung-infection with in neutropenic mice. In thigh-infected mice, the PAE was negative (-2.18 to -0.11 h) for...
8.
In-vitro pharmacokinetic/pharmacodynamic model data suggest a potential role of new formulations of posaconazole against Candida krusei but not Candida glabrata infections
Beredaki M, Arendrup M, Mouton J, Meletiadis J
Int J Antimicrob Agents . 2021 Jan; 57(3):106291. PMID: 33508404
Posaconazole exhibits in-vitro activity against Candida glabrata and Candida krusei. Epidemiological cut-off values set by the European Committee on Antimicrobial Susceptibility Testing (EUCAST) and the Clinical and Laboratory Standards Institute...
9.
The Role of New Posaconazole Formulations in the Treatment of Candida albicans Infections: Data from an Pharmacokinetic-Pharmacodynamic Model
Beredaki M, Arendrup M, Andes D, Mouton J, Meletiadis J
Antimicrob Agents Chemother . 2021 Jan; 65(4). PMID: 33468486
Posaconazole is more active than fluconazole against and is approved for the treatment of oropharyngeal candidiasis but not for that of invasive candidiasis (IC). Here, we explored the efficacy of...
10.
Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in Checkerboard Assays
Kloezen W, Melchers R, Georgiou P, Mouton J, Meletiadis J
Antimicrob Agents Chemother . 2021 Jan; 65(4). PMID: 33431413
Extended-spectrum-β-lactamase (ESBL)-producing strains are increasing worldwide, limiting therapeutic options. Taniborbactam (VNRX-5133) is a newly developed β-lactamase inhibitor with a wide spectrum of activity covering both serine and metallo enzymes. We...